AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12121601 — intervention group
Group type: EXPERIMENTAL
Intervention: Twinrix vaccine (combined hepatitis A and B vaccine) administered on a 0‐, 1‐ and 6‐month schedule
Number of subjects: 345
Study 10486488 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple courses of antenatal corticosteroids (2 or more courses)
Number of subjects: 710
Study 10486488 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple courses of antenatal corticosteroids (3 or more courses)
Number of subjects: 710
Study 10486488 — intervention group
Group type: COMPARATOR
Intervention: Single course of antenatal corticosteroids
Number of subjects: 710
Study 10486488 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple courses of antenatal corticosteroids
Number of subjects: 710
Study 8943591 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine via patient controlled analgesia and local cooling of the wound by an externally applied cooling pad
Number of subjects: 30
Study 8943591 — intervention group
Group type: COMPARATOR
Intervention: Patient controlled analgesia alone
Number of subjects: 30
Study 1912407 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-protein and low-phosphorus diets
Number of subjects: 0
Study 1912407 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of follow-up
Number of subjects: 0
Study 1912407 — intervention group
Group type: EXPERIMENTAL
Intervention: Regression to the mean
Number of subjects: 0
Study 1912407 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean follow-up period
Number of subjects: 0
Study 6177371 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-Dihydroergotamine (DHE)
Number of subjects: 7413
Study 6177371 — intervention group
Group type: COMPARATOR
Intervention: Dextran 70
Number of subjects: 7413
Study 31941531 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-kHz spinal cord stimulation (SCS) combined with conventional medical management (CMM)
Number of subjects: 216
Study 31941531 — intervention group
Group type: COMPARATOR
Intervention: Conventional medical management (CMM) alone
Number of subjects: 216
Study 30153062 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinect training
Number of subjects: 75
Study 30153062 — intervention group
Group type: COMPARATOR
Intervention: Conventional balance training
Number of subjects: 75
Study 30153062 — intervention group
Group type: COMPARATOR
Intervention: No-intervention control
Number of subjects: 75
Study 29037222 — intervention group
Group type: EXPERIMENTAL
Intervention: ICT-based centralized home monitoring system
Number of subjects: 114
Study 29037222 — intervention group
Group type: COMPARATOR
Intervention: Ambulatory follow-up
Number of subjects: 114
Study 26378828 — intervention group
Group type: EXPERIMENTAL
Intervention: YMCA adaptation of the Diabetes Prevention Program (YDPP)
Number of subjects: 509
Study 26378828 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 509
Study 25231496 — intervention group
Group type: EXPERIMENTAL
Intervention: Community intervention: symptom awareness campaign tailored for rural Australians.
Number of subjects: 1350
Study 25231496 — intervention group
Group type: EXPERIMENTAL
Intervention: GP intervention: resource card with symptom risk assessment charts and local referral pathways.
Number of subjects: 1350
Study 22714063 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal administration of Cyclogest (400 mg, twice daily for up to 8 weeks)
Number of subjects: 147
Study 22714063 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal administration of Cyclogest (400 mg, twice daily for up to 8 weeks)
Number of subjects: 147
Study 22714063 — intervention group
Group type: COMPARATOR
Intervention: Both vaginal and rectal administration of Cyclogest
Number of subjects: 147
Study 20845015 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Number of subjects: 17
Study 20845015 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Number of subjects: 17
Study 20845015 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine
Number of subjects: 17
Study 20845015 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine, Ropivacaine, Levobupivacaine
Number of subjects: 17
Study 17674518 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium enriched food supplement based on spirulina
Number of subjects: 80
Study 17674518 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 80
Study 15598451 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI examination of the injured knee during leg-press against resistance
Number of subjects: 31
Study 15598451 — intervention group
Group type: COMPARATOR
Intervention: MRI examination of the loaded knees
Number of subjects: 31
Study 15598451 — intervention group
Group type: EXPERIMENTAL
Intervention: ACL injury
Number of subjects: 31
Study 12360176 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct stent implantation (DS+)
Number of subjects: 338
Study 12360176 — intervention group
Group type: COMPARATOR
Intervention: Standard stent implantation with balloon predilatation (DS-)
Number of subjects: 338
Study 10710009 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferrum H (5x2ml intramuscular injections)
Number of subjects: 15
Study 10710009 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (Placebo Group)
Number of subjects: 15
Study 7749807 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil (10 to 12 weeks)
Number of subjects: 21
Study 7749807 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 2264362 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral immunization with 'Influmun' from SSW Dresden, GDR
Number of subjects: 360
Study 2264362 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral immunization with an inactivated influenza vaccine using enteric-coated capsules
Number of subjects: 360
Study 2264362 — intervention group
Group type: COMPARATOR
Intervention: Non-immunized group
Number of subjects: 360
Study 2264362 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunized groups (both parenteral and oral)
Number of subjects: 360
Study 7041579 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (Trental 400 mg coated tablets)
Number of subjects: 60
Study 7041579 — intervention group
Group type: COMPARATOR
Intervention: Nylidrin HCl (3 mg)
Number of subjects: 60
Study 30529451 — intervention group
Group type: EXPERIMENTAL
Intervention: ACET Program (computerized decision support tool)
Number of subjects: 0
Study 28745656 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 0.1% and diclofenac 0.1% (n=20 eyes, Group I)
Number of subjects: 40
Study 28745656 — intervention group
Group type: COMPARATOR
Intervention: Bromfenac 0.09% (n=20 eyes, Group II)
Number of subjects: 40
Study 25397788 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized Prolate Ablation (OPA)
Number of subjects: 53
Study 25397788 — intervention group
Group type: COMPARATOR
Intervention: Optical Path Difference Custom Aspheric Treatment (OPDCAT)
Number of subjects: 53
Study 23820974 — intervention group
Group type: EXPERIMENTAL
Intervention: Active 890-nm light therapy combined with hot-pack therapy
Number of subjects: 60
Study 23820974 — intervention group
Group type: COMPARATOR
Intervention: Placebo 890-nm light therapy combined with hot-pack therapy
Number of subjects: 60
Study 18040527 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine therapy
Number of subjects: 0
Study 18040527 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine and vitamin E therapy
Number of subjects: 0
Study 18040527 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 14986189 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training (Square-Wave Endurance Exercise Test) for 6 weeks
Number of subjects: 15
Study 14986189 — intervention group
Group type: COMPARATOR
Intervention: Control group (daily activities)
Number of subjects: 15
Study 10606908 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 10 per cent phenylephrine
Number of subjects: 36
Study 10606908 — intervention group
Group type: COMPARATOR
Intervention: Placebo gels
Number of subjects: 36
Study 9352981 — intervention group
Group type: EXPERIMENTAL
Intervention: Alteplase
Number of subjects: 146
Study 9352981 — intervention group
Group type: COMPARATOR
Intervention: Streptokinase
Number of subjects: 146
Study 9352981 — intervention group
Group type: COMPARATOR
Intervention: Combination of streptokinase and alteplase
Number of subjects: 146
Study 9352981 — intervention group
Group type: EXPERIMENTAL
Intervention: Irrespective of treatment
Number of subjects: 146
Study 10124199 — intervention group
Group type: EXPERIMENTAL
Intervention: Rural residents with a history of depressive symptoms
Number of subjects: 200
Study 10124199 — intervention group
Group type: COMPARATOR
Intervention: Urban residents with a history of depressive symptoms
Number of subjects: 200
Study 10124199 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative labeling
Number of subjects: 200
Study 3739811 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine delivered in research cigarettes
Number of subjects: 25
Study 3739811 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine delivered in tobacco snuff
Number of subjects: 25
Study 31510943 — intervention group
Group type: EXPERIMENTAL
Intervention: Birth at health facility
Number of subjects: 226
Study 31510943 — intervention group
Group type: COMPARATOR
Intervention: Birth at home
Number of subjects: 226
Study 28835513 — intervention group
Group type: EXPERIMENTAL
Intervention: pembrolizumab (200 mg IV every 3 weeks)
Number of subjects: 2
Study 28835513 — intervention group
Group type: EXPERIMENTAL
Intervention: pembrolizumab (2 mg/kg IV every 3 weeks)
Number of subjects: 2
Study 28835513 — intervention group
Group type: EXPERIMENTAL
Intervention: pembrolizumab (10 mg/kg IV every 3 weeks)
Number of subjects: 2
Study 28835513 — intervention group
Group type: COMPARATOR
Intervention: docetaxel (75 mg/m2 every 3 weeks)
Number of subjects: 2
Study 25979373 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional laboratory screening for STIs before IUC insertion
Number of subjects: 672
Study 25979373 — intervention group
Group type: COMPARATOR
Intervention: No additional screening for STIs before IUC insertion
Number of subjects: 672
Study 25979373 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (additional laboratory screening and no additional screening)
Number of subjects: 672
Study 24092379 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand‐assisted retroperitoneoscopic donor nephrectomy (HARP)
Number of subjects: 190
Study 24092379 — intervention group
Group type: COMPARATOR
Intervention: Standard laparoscopic donor nephrectomy (LDN)
Number of subjects: 190
Study 21295842 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,000 IU hCG
Number of subjects: 719
Study 21295842 — intervention group
Group type: COMPARATOR
Intervention: 1 mL saline (control)
Number of subjects: 719
Study 19413790 — intervention group
Group type: EXPERIMENTAL
Intervention: MRC+I (motivated referral condition with monetary incentives)
Number of subjects: 281
Study 19413790 — intervention group
Group type: COMPARATOR
Intervention: MRC (motivated referral condition)
Number of subjects: 281
Study 19413790 — intervention group
Group type: COMPARATOR
Intervention: SRC (standard referral condition)
Number of subjects: 281
Study 16890770 — intervention group
Group type: EXPERIMENTAL
Intervention: Environmental tobacco smoke (ETS)
Number of subjects: 19
Study 16890770 — intervention group
Group type: COMPARATOR
Intervention: Clean air
Number of subjects: 19
Study 15610829 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured group counseling program (cognitive-behavioral relapse prevention approach)
Number of subjects: 97
Study 15610829 — intervention group
Group type: COMPARATOR
Intervention: Naltrexone treatment (50 mg daily)
Number of subjects: 97
Study 11726444 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine 10 microg
Number of subjects: 36
Study 11726444 — intervention group
Group type: COMPARATOR
Intervention: Control (no neostigmine)
Number of subjects: 36
Study 9425673 — intervention group
Group type: EXPERIMENTAL
Intervention: Older adults (65 years old)
Number of subjects: 2
Study 9425673 — intervention group
Group type: COMPARATOR
Intervention: Younger adults (20 years old)
Number of subjects: 2
Study 8503715 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (n = 8) reheated between 10 and 25 minutes
Number of subjects: 17
Study 8503715 — intervention group
Group type: COMPARATOR
Intervention: Group B (n = 9) reheated between 26 and 50 minutes
Number of subjects: 17
Study 3324563 — intervention group
Group type: EXPERIMENTAL
Intervention: Clenbuterol tablets (40 micrograms twice daily, later 20 micrograms twice daily)
Number of subjects: 61
Study 3324563 — intervention group
Group type: COMPARATOR
Intervention: Fenoterol perlongettes
Number of subjects: 61
Study 29135651 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir film (40 mg)
Number of subjects: 10
Study 29135651 — intervention group
Group type: COMPARATOR
Intervention: Tenofovir gel (1% 40 mg)
Number of subjects: 10
Study 27263068 — intervention group
Group type: EXPERIMENTAL
Intervention: Refeeding
Number of subjects: 15
Study 25027267 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based educational intervention with an average of ten prenatal home visits from a trained mentor providing information on healthy prenatal behaviours and social support.
Number of subjects: 233
Study 25027267 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based educational intervention
Number of subjects: 233
Study 25027267 — intervention group
Group type: COMPARATOR
Intervention: Control group received care as usual including standard antenatal classes.
Number of subjects: 233
Study 22682082 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk protein sip feeding (Whey protein meal)
Number of subjects: 0
Study 19627427 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 86
Study 19627427 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 86
Study 19627427 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 18176233 — intervention group
Group type: EXPERIMENTAL
Intervention: Juvéderm Ultra Plus
Number of subjects: 87
Study 18176233 — intervention group
Group type: COMPARATOR
Intervention: Zyplast collagen
Number of subjects: 87
Study 15695979 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooperative group trials for Stage IB 2 disease treated with radiation therapy
Number of subjects: 2075
Study 15695979 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooperative group trials
Number of subjects: 2075
Study 15695979 — intervention group
Group type: COMPARATOR
Intervention: SEER database
Number of subjects: 2075
Study 12471626 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV DNA testing
Number of subjects: 863
Study 12471626 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-VLPs testing for HPV types 16, 18, 31, 33, and 58
Number of subjects: 863
Study 12471626 — intervention group
Group type: EXPERIMENTAL
Intervention: Age-standardized prevalence of HPV DNA
Number of subjects: 863
Study 12471626 — intervention group
Group type: EXPERIMENTAL
Intervention: Age-standardized prevalence of anti-VLPs
Number of subjects: 863
Study 12471626 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors for HPV DNA and anti-VLPs
Number of subjects: 863
Study 12471626 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV DNA prevalence among women whose husbands were thought to have extra-marital affairs
Number of subjects: 863
Study 12471626 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV DNA prevalence among women who had undergone vasectomy
Number of subjects: 863
Study 12471626 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-VLPs prevalence among virgins
Number of subjects: 863
Study 10629347 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 10629347 — intervention group
Group type: COMPARATOR
Intervention: Glycine 0.5 g/day
Number of subjects: 200
Study 10629347 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycine 1.0 g/day
Number of subjects: 200
Study 10629347 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycine 2.0 g/day
Number of subjects: 200
Study 8853584 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 613
Study 1353607 — intervention group
Group type: COMPARATOR
Intervention: 500 mg per day of didanosine
Number of subjects: 913
Study 1353607 — intervention group
Group type: COMPARATOR
Intervention: 750 mg per day of didanosine
Number of subjects: 913
Study 1353607 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg per day of zidovudine
Number of subjects: 913
Study 6375804 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg metronidazole three times daily for seven days
Number of subjects: 429
Study 6375804 — intervention group
Group type: EXPERIMENTAL
Intervention: 2000 mg metronidazole as a single dose
Number of subjects: 429
Study 6375804 — intervention group
Group type: EXPERIMENTAL
Intervention: 2000 mg metronidazole on days 1 and 2
Number of subjects: 429
Study 6375804 — intervention group
Group type: EXPERIMENTAL
Intervention: 2000 mg metronidazole on days 1 and 3
Number of subjects: 429
Study 6375804 — intervention group
Group type: EXPERIMENTAL
Intervention: 1200 mg metronidazole once daily for five days
Number of subjects: 429
Study 31587102 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol 50 mg
Number of subjects: 22
Study 31587102 — intervention group
Group type: COMPARATOR
Intervention: Allopurinol 100 mg
Number of subjects: 22
Study 30290598 — intervention group
Group type: EXPERIMENTAL
Intervention: Scalp acupuncture combined with cognitive training
Number of subjects: 60
Study 30290598 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment and cognitive rehabilitation training
Number of subjects: 60
Study 26965760 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher salt intake group (>=10.0 g/day, n=362)
Number of subjects: 793
Study 26965760 — intervention group
Group type: COMPARATOR
Intervention: Lower salt intake group (<10.0 g/day, n=431)
Number of subjects: 793
Study 23980239 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine mouth-rinse (35 mg of anhydrous caffeine in 25 ml for 10 s, administered eight times)
Number of subjects: 10
Study 23980239 — intervention group
Group type: COMPARATOR
Intervention: Placebo mouth-rinse (25 ml for 10 s, administered eight times)
Number of subjects: 10
Study 23980239 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine mouth-rinse
Number of subjects: 10
Study 23980239 — intervention group
Group type: COMPARATOR
Intervention: Placebo mouth-rinse
Number of subjects: 10
Study 22755506 — intervention group
Group type: EXPERIMENTAL
Intervention: Dutasteride treatment (duration not specified)
Number of subjects: 142
Study 20210592 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation (FES) therapy
Number of subjects: 30
Study 20210592 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 30
Study 17011248 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibenclamide 3.5 mg per dose
Number of subjects: 0
Study 15823823 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone 2.5 mg/day for 28 days
Number of subjects: 61
Study 15823823 — intervention group
Group type: COMPARATOR
Intervention: Sequential estrogen-progestogen therapy (0.625 mg CEE for 25 days + 5 mg MPA on days 16-25)
Number of subjects: 61
Study 15823823 — intervention group
Group type: COMPARATOR
Intervention: Sequential estrogen-progestogen therapy
Number of subjects: 61
Study 11991622 — intervention group
Group type: EXPERIMENTAL
Intervention: rebamipide (300 mg daily for 12 months)
Number of subjects: 86
Study 11991622 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 86
Study 9850405 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral halofantrine 8 mg/kg body weight every 6 h for 3 doses
Number of subjects: 42
Study 8720766 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine
Number of subjects: 16
Study 8720766 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide
Number of subjects: 16
Study 2809856 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) 300 mg daily for 1 week, followed by 3.4 g eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) for 4 weeks
Number of subjects: 22
Study 2809856 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.4 g daily of EPA and DHA for 4 weeks, followed by ASA 300 mg daily for 1 week
Number of subjects: 22
Study 1124175 — intervention group
Group type: EXPERIMENTAL
Intervention: Copper T 300
Number of subjects: 776
Study 1124175 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalkon Shield
Number of subjects: 776
Study 1124175 — intervention group
Group type: EXPERIMENTAL
Intervention: Shell Loop
Number of subjects: 776
Study 31343517 — intervention group
Group type: EXPERIMENTAL
Intervention: Fermented soy extract (30 g powdered supplement in 16 fl. ounces of water)
Number of subjects: 25
Study 31343517 — intervention group
Group type: COMPARATOR
Intervention: Placebo (same quantities of organic cocoa powder and water)
Number of subjects: 25
Study 31278924 — intervention group
Group type: EXPERIMENTAL
Intervention: High-load intradialytic group (HLG, 8-10 repetitions)
Number of subjects: 80
Study 31278924 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-load intradialytic group (MLG, 16-18 repetitions)
Number of subjects: 80
Study 31278924 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG, stretching exercise)
Number of subjects: 80
Study 31278924 — intervention group
Group type: EXPERIMENTAL
Intervention: Both RT protocols (HLG and MLG)
Number of subjects: 80
Study 31278924 — intervention group
Group type: EXPERIMENTAL
Intervention: High-load intradialytic group (HLG)
Number of subjects: 80
Study 31278924 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-load intradialytic group (MLG)
Number of subjects: 80
Study 28817535 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel (60 mg loaded before PCI)
Number of subjects: 94
Study 28817535 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel (dual antiplatelet therapy)
Number of subjects: 94
Study 28817535 — intervention group
Group type: COMPARATOR
Intervention: Genotyping
Number of subjects: 94
Study 28817535 — intervention group
Group type: COMPARATOR
Intervention: PFT
Number of subjects: 94
Study 28817535 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 94
Study 25294250 — intervention group
Group type: EXPERIMENTAL
Intervention: Oritavancin (single intravenous 1200-mg dose)
Number of subjects: 1005
Study 25294250 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin (7-10 days of twice-daily treatment)
Number of subjects: 1005